Abbott, ProMetic Pacts With Red Cross Cover Blood Screening, TSE Removal
This article was originally published in The Gray Sheet
Executive Summary
The American Red Cross will retain a 74% equity stake in a joint venture with ProMetic Life Sciences to develop systems for detection and removal of transmissible spongiform encephalopathy (TSE) pathogens from blood and blood components